Prospective, Randomized, Single-Blinded, Multi-Center Phase II Trial of the HER2/neu Peptide GP2 + GM-CSF Vaccine versus GM-CSF Alone in HLA-A2+ OR the Modified HER2/neu Peptide AE37 + GM-CSF Vaccine versus GM-CSF Alone in HLA-A2- Node-Positive and High-R

The main objectives of the trial are to determine if the GP2 + GM-CSF vaccine reduces the recurrence rate in HLA-A2+, HER2/neu+, node-positive or high-risk node-negative breast cancer patients randomized to receive either the vaccine versus the immunoadjuvant, GM-CSF, alone. Also to determine if the AE37 + GM-CSF vaccine reduces the recurrence rate in HLA-A2-, HER2/neu+, node-positive or high-risk node-negative breast cancer patients randomized to receive either the vaccine versus the immunoadjuvant, GM-CSF, alone.